Genetic Risk Assessment in Thailand: Cost, Top Clinics & What to Expect

A genetic risk assessment uses polygenic risk scores to evaluate your cumulative predisposition to common multifactorial diseases. Unlike single-gene tests that look for one high-impact mutation at a time, polygenic scoring analyses hundreds of thousands of common variants across your genome and combines them into a single risk metric for each condition. The result is a personalised risk profile that shows where you sit relative to the general population.

The clinical utility is in prevention planning. If your cardiovascular polygenic risk score places you in the top five per cent, that changes when screening starts and how aggressively risk factors are managed. If your breast cancer score is elevated, it may justify earlier mammography. These are not speculative predictions — they are validated risk stratification tools used in research settings that are now available clinically. Your genetic counsellor interprets the scores alongside family history and lifestyle factors to produce a practical prevention plan.

A comprehensive genetic risk assessment in Thailand typically costs between $500 and $800, depending on the scope — a standard multi-disease panel at the lower end, a combined polygenic-plus-exome analysis at the higher end.

The total covers initial consultation, sample collection, certified laboratory genotyping, polygenic risk score computation, a comprehensive written report, post-test genetic counselling, and a personalised prevention plan. A care coordinator supports you throughout the process.

Scope is the main variable. A standard multi-disease polygenic panel costs less than an analysis that adds targeted exome sequencing for high-penetrance variants. Integrated risk modelling that incorporates clinical biomarkers increases the total further. Your specialist recommends the scope that matches your clinical question and budget.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• Single-condition risk panel (e.g. cardiac or cancer): $500–$580 — targeted panel screening for one category of hereditary risk
• Multi-condition risk panel: $580–$700 — broader screening covering cardiac, cancer, neurological, and metabolic risks
• Comprehensive risk assessment with genetic counselling: $700–$800 — full panel plus a one-on-one session with a certified genetic counsellor

Exact pricing is confirmed after your consultation and treatment plan are finalised.

Genetic risk assessment in Thailand costs 50–70% less than equivalent screening at genetics clinics in the US ($1,000–$2,000), Australia (A$900–A$1,750), and UK (£800–£1,500). The savings come from lower clinical costs while using equivalent genotyping platforms, validated algorithms, and certified counsellors.

Immediately. The assessment involves a blood draw or saliva sample and nothing more. There are no travel restrictions. Many patients complete sample collection as part of a broader health screening trip and fly home the same day. Results are delivered remotely.

No. Genotyping and analysis take two to three weeks. The results consultation can be conducted via secure video call from anywhere in the world. You do not need to remain in Thailand for the interpretation session.

Your genetic counsellor helps you translate scores into a practical plan: adjusted screening schedules, targeted lifestyle modifications, and — where appropriate — referrals to condition-specific specialists. Your report is designed for ongoing use by your home medical team.

PRS models have been validated in large biobank studies involving hundreds of thousands of participants. They reliably identify individuals at the highest and lowest ends of the risk spectrum for major conditions. However, they are probabilistic — an elevated score increases the likelihood of a condition but does not guarantee it will develop. Your counsellor explains this distinction clearly during your consultation.

Polygenic scores are most validated in populations of European ancestry. Prediction accuracy may be lower for individuals of other ancestral backgrounds, though this gap is narrowing as global biobank data expands. Additionally, risk scores reflect genetic susceptibility only — lifestyle, environment, and other factors significantly modify actual disease risk. Your counsellor contextualises your scores with these factors.

Because genetic risk is inherited, your results may have implications for biological relatives. Your counsellor can discuss how to approach these conversations and what testing might be relevant for family members. Sharing your results with relatives is always your decision — the clinic will not contact family members without your explicit request.

Our partner clinics use accredited laboratories that run validated genotyping platforms — the same arrays used in major international biobank studies. The analysis pipelines use peer-reviewed algorithms published in high-impact journals. This is not consumer-grade genotyping repurposed for clinical use — it is clinical genetics infrastructure from the ground up.

The counsellors interpreting your results hold board certification in genetic counselling with training at internationally recognised institutions. Their role is not just to present numbers — it is to explain what elevated or low-risk scores mean in practical terms, what screening adjustments are warranted, and what the evidence does and does not support.

Ask which genotyping platform is used and whether the PRS algorithms are published and validated. Check that a certified genetic counsellor — not just a general physician — reviews and presents your results. Confirm that the report includes clear methodology documentation so your home physician can evaluate the results in context.

A personalised risk profile showing your polygenic risk score for each assessed condition, expressed as a population-relative percentile. Each score is contextualised with your family history and — where applicable — clinical biomarker data. The report includes a prioritised prevention plan with specific screening recommendations and lifestyle modification targets.

The most common action is adjusting screening schedules — earlier cardiovascular screening for high-risk patients, more frequent cancer surveillance where warranted. Some patients share their pharmacogenomic component with prescribers. Others use the data to motivate lifestyle changes that specifically target their highest-risk areas. The results are a permanent reference that your medical team can use throughout your life.

One to two days is sufficient. Sample collection and initial consultation are completed in a single visit of 30 to 60 minutes. Results are delivered remotely two to three weeks later. Many patients combine this with a health screening or DNA testing programme, using the same trip for multiple assessments.

Your programme fee covers consultation, sample collection, laboratory genotyping, score computation, written report, genetic counselling, and a personalised prevention plan. A care coordinator handles scheduling and follow-up. International data transfer and secure storage are included.

Genetic risk assessment pairs efficiently with DNA testing, pharmacogenomic testing, or a full body health screen. Collecting samples for multiple tests in a single visit saves time and cost. Your coordinator can schedule everything into a streamlined one-to-two-day programme.